{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:13:42Z","timestamp":1788491622241,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T00:00:00Z","timestamp":1425686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1104-5","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T21:00:29Z","timestamp":1425675629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Sigita","family":"Liutkauskiene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Janciauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Jureniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saulius","family":"Grizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Malonyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Juozaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,7]]},"reference":[{"issue":"Suppl. 6","key":"1104_CR1","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi24\u201332.","journal-title":"Ann Oncol"},{"key":"1104_CR2","unstructured":"EUCAN cancer factsheets: ovary. [ http:\/\/eu-cancer.iarc.fr\/EUCAN\/CancerOne.aspx?Cancer=27&Gender=2 ]"},{"issue":"Suppl.3","key":"1104_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","volume":"89","author":"WP McGuire 3rd","year":"2003","unstructured":"McGuire 3rd WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89(Suppl3):S3\u20138.","journal-title":"Br J Cancer"},{"key":"1104_CR4","first-page":"101","volume":"42","author":"CT Griffiths","year":"1975","unstructured":"Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101\u20134.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"4","key":"1104_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","volume":"170","author":"WJ Hoskins","year":"1994","unstructured":"Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1104_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0090-8258(90)90042-J","volume":"38","author":"K Bertelsen","year":"1990","unstructured":"Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 1990;38(2):203\u20139.","journal-title":"Gynecol Oncol"},{"issue":"18","key":"1104_CR7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","volume":"38","author":"J Engel","year":"2002","unstructured":"Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, et al. Moderate progress for ovarian cancer in the last 20\u00a0years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002;38(18):2435\u201345.","journal-title":"Eur J Cancer"},{"issue":"17","key":"1104_CR8","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"3 Pt 1","key":"1104_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","volume":"108","author":"JK Chan","year":"2006","unstructured":"Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14\u00a0years. Obstet Gynecol. 2006;108(3 Pt 1):521\u20138.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"1104_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3109\/02841861003691945","volume":"49","author":"A Klint","year":"2010","unstructured":"Klint A, Tryggvad\u00f3ttir L, Bray F, Gislum M, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964\u20132003 followed up to the end of 2006. Acta Oncol. 2010;49(5):632\u201343.","journal-title":"Acta Oncol"},{"issue":"3","key":"1104_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1471-0528.2008.02033.x","volume":"116","author":"CG Gerestein","year":"2009","unstructured":"Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG. 2009;116(3):372\u201380.","journal-title":"BJOG"},{"issue":"3","key":"1104_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1006\/gyno.2001.6328","volume":"82","author":"DS Chi","year":"2001","unstructured":"Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82(3):532\u20137.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1104_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","volume":"124","author":"CI Nagel","year":"2012","unstructured":"Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O\u2019Malley DM, et al. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2012;124(2):221\u20134.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1104_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0959-8049(03)00152-7","volume":"39","author":"C Dittrich","year":"2003","unstructured":"Dittrich C, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin\u2013cisplatin with cyclophosphamide\u2013cisplatin. Eur J Cancer. 2003;39(8):1129\u201340.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1104_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.1997.15.1.193","volume":"15","author":"A Jakobsen","year":"1997","unstructured":"Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose\u2013effect study of carboplatin in ovarian cancer: a danish ovarian cancer group study. J Clin Oncol. 1997;15(1):193\u20138.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1104_CR16","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","volume":"21","author":"GA Omura","year":"2003","unstructured":"Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003;21(15):2843\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1104_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","volume":"122","author":"JM Fauci","year":"2011","unstructured":"Fauci JM, Whitworth JM, Schneider KE, Subramaniam A, Zhang B, Frederick PJ, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):532\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1104_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","volume":"129","author":"RK Hanna","year":"2013","unstructured":"Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74\u201380.","journal-title":"Gynecol Oncol"},{"key":"1104_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2407-11-131","volume":"11","author":"S Loibl","year":"2011","unstructured":"Loibl S, Skacel T, Nekljudova V, L\u00fcck HJ, Schwenkglenks M, Brodowicz T, et al. Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer a pooled analysis. BMC Cancer. 2011;11:131.","journal-title":"BMC Cancer"},{"issue":"2","key":"1104_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","volume":"3","author":"E Culakova","year":"2014","unstructured":"Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity andsupportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434\u201344.","journal-title":"Cancer Med"},{"issue":"2","key":"1104_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ygyno.2007.04.012","volume":"106","author":"EL Eisenhauer","year":"2007","unstructured":"Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, et al. Response and outcomes in elderly patients with stages IIIC\u2013IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106(2):381\u20137.","journal-title":"Gynecol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1104-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1104-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T15:55:48Z","timestamp":1598802948000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1104-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,7]]},"article-number":"105"}}